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Abstract
Stroke is a frequent cause of disability in U.S.A. (200.000/
year).
Aim: The aim of this study is to underline the effect of low dose
of Rotigotine patches 2 mg/24 h, a complete dopamine agonist
with continuous dopaminergic stimulation through the trans-
dermal administration, in elderly with recent stroke and
vascular Parkinsonism about quality of life and adherence to
rehabilitation therapy.
Methods: We have enrolled 6 elderly patients (3 males and 3
females, range age 60 – 95 years) with recent ischemic and
vascular Parkinsonism. We have evaluated quality of life and
cognitive function with UPDRS part III, MMSE, ADL, IADL and
Morinsky Scale. At the same time we have evaluated the
adherence to therapy and timing of rehabilitation therapy
before and post-administration of Rotigotine 2 mg/24 hours.
Conclusion: In conclusion, Rotigotine could be a new useful
approach in the treatment of elderly patients with recent
ischemic and hemorrhagic stroke correlated with vascular
Parkinsonism which can lead to an akinesia with the need to
start rehabilitation therapy. Our preliminary data gives
comfortable results but, at this time, we have enrolled only few
patients to give conclusive results.
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Introduction
Stroke is a frequent cause of disability in U.S.A. (200.000/year) and
~ 85% are ischemic while ~ 15% are primary hemorrhages. An
ischemic deficit without radiologic evidence of an infarction is termed
TIA. After 24 h, the neurological deficit is termed Stroke.
The aim of this study is to underline the effect of low dose of
Rotigotine patches 2 mg/24 h, a complete dopamine agonist
D3>D2>D1 with continuous dopaminergic stimulation through the
transdermal administration, in elderly with recent stroke and vascular
Parkinsonism about quality of life and adherence to rehabilitation
therapy.
In a recent review Sami et al. suggest that administration of
dopaminergic agents have long been associated with improvements of
neuropsychiatric outcomes [1]. More data in the literature underlines
that administration of dopaminergic agents have long been associated
with improvements of outcome after stroke and show that patient care,
in comprehensive stroke units followed by rehabilitation service,
improves neurological outcomes and reduces mortality.
Materials and Methods
We have enrolled 6 elderly patients (3 males and 3 females, range
age 60 – 95 years) with recent ischemic stroke that have developed a
vascular Parkinsonism. We have evaluated quality of life and cognitive
function with UPDRS part III, MMSE, ADL, IADL and Morinsky
Scale. At the same time we have evaluated the adherence to therapy
and timing of rehabilitation therapy before and post-administration of
Rotigotine 2 mg/24 hours.
We have studied enrolled patients using international scale and
standard Holter-ECG to register HR variability. In a recent review
Valderiolla et al. suggest the effects of Night-Time Rotigotine on
nocturnal symptoms in Parkinson's disease [2].
Statistical analysis is performed using Sigmastat analysis program
version 3.5. We have escluded patients in therapy with anti-arrhitmics
drugs to evoid bias in HR-variability. All the patients provided written
informed consent. Eligibility requirements at screening included age of
at least 18 years.
Figure 1: Multi-dimensional evaluation pre and post Rotigotine.
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Results
Preliminary data are about 6 patients with vascular Parkinsonism (3
F and 3 M) with mean age 78 yrs (range 70 to 86 yrs) after treatment
with Rotigotine 2 mg/24 h. At the end of treatment we obtained a
statistically significative correlation about improvement of MMSE
from a basal value. Siilar aspects are noted about Multi-Dimensional
Evaluation (IADL AND UPDRS PART III) (Figure 1), severity of
oxygen Desaturation and Obstructive Sleep Apnea Syndrome (OSAS)
[3]. Two patients are excluded: 1 female for severe cognitive
impairment, MMSE, ADL and IADL not administrable and 1 male for
hemorrhagic complication. Further and follow-up period are needed
to have more significant results (Figure 2).
Figure 2: Cognitive profile pre and post Rotigotine,
Discussion
Our study was designed to provide evidence to support the
replacement of rotigotine patches in the management of Parkinsonism
due to acute ischemic stroke. The mean dose of rotigotine that was
used in our study (2 mg daily) was lower than the doses used in the
Parkinson diseases and Parkinsonism and that showed a benefit with
rotigotine patches 2 mg/24 h in patients with mild to moderate
symptoms of Parkinsonism due to acute ischemic stroke (Figure 3).
Figure 3: Blood presure profile pre and post Rotigotine.
This experience led us to prescribe rotigotine patches 2 mg/24 h
despite its once-daily efficacy in patients with Parkinsonism and recent
ischemic stroke. Rotigotine patches 2 mg/24 h were effective and well-
tolerated when used in routine clinical practice. (Table 1).
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Table 1: Descriptive Statistics: Analysis of preliminary data.
Preliminary data shows that there are not significant correlations
behind Morinsky scale (due to different drugs management during
hospitalization period), number of swallows for minute, OSAS, and
Heart Rate Variability (Table 2).
In literature there are a lot of reviews that describe the differents
positive effects of Rotigone: improves sleep in Parkinson's disease [6]
and improves sleep fragmentation in Parkinson's disease [7].
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Table 2: Descriptive Statistics: Analysis of preliminary data.
We have noted an improvement of clinical neuropsychiatric
outcomes: especially the apathy [5], aphasia, dysphagia [4] and
anhedonia but without statistically significant correlation.
Moreover is described the neurophysiological effects of transdermal
Rotigotine in atypical Parkinsonism [8] (Figure 4).
Figure 4: Smootnes and peak/valley index pre and post Rotigotine.
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Figure 5: Heart rate variability pre and post Rotigotine.
Only 0.6% of patients did not complete the follow-up because of
adverse events. Hence our results are not applicable to a broad
spectrum of patients with Parkinsonism due to acute ischemic stroke
(Figure 5).
Conclusion
Rotigotine could be a new useful approach in the treatment of
elderly patients with recent ischemic stroke and vascular Parkinsonism
which can lead to an akinesia with the need to start rehabilitation
therapy. Our preliminary data gives comfortable results but, at this
time, we have enrolled only few patients to give conclusive results.
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